Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of frailty on the median effective dose of sufentanil for rigid bronchoscopy in elderly patients
ChiCTR2300077214Phase 4Not yet recruiting
- Sponsor
- Peking University First Hospital
- Start
- Nov 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of sufentanil in Fragility, procedural pain and None (2 arms), sponsored by Peking University First Hospital. Primary endpoint: Median effective dose (ED50) of sufentanil to blunt rigid bronchoscope insertion response. Planned start Nov 2023; status: not yet recruiting.
02
Drugs
sufentanil
03
Conditions
Fragilityprocedural pain
Beyond the preview
Go deeper on ChiCTR2300077214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300077214.